No one in the right mind would by FRX, they have no know how to speak of and bunch of mee-too drugs that are expiring one by one. They are hoping IBS drug will get some money in, but the rest of the #$%$ they push through FDA are all old news drugs that are no better than existing #$%$. They going to be losing revenues and cash because their CEO has no vision and VP of clinical is a Soviet-style bureaucrat with zero ideas. One cannot be competitive in Pharma world by producing aspirin.
• I Forest Labs is in a unique situation where it has too many new drugs to launch. Among
its ..........drugs the company assembled to replace Lexapro and
Namenda, 7 have been launched: Bystolic, Savella, Viibryd, Teflaro,
Linzess, Daliresp and Tudorza. The other 2 ,
levomilnacipran has a PDUFA date this month, while cariprazine is also
under FDA review. ..... Forest has also just launched Namenda
XR, ............ it is likely the 3 co-formulated
drugs, Tudorza + formoterol, Bystolic + valsartan, and ceftazidime +
avibactam, will reach the US market in the near future.
Tudorza + formoterol will be filed for FDA approval by the end of this
year. , FRX is potentially introducing 13 new drugs into the
US branded pharma mkt